Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

BACKGROUND: Although number of elderly patients with metastatic colorectal cancer (mCRC) is rapidly increasing, this population is often underrepresented in clinical trials. Recently, a phase II trial demonstrated that capecitabine and oxaliplatin (XELOX) combined with bevacizumab XELOX plus bevaciz...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Munemoto, Yoshinori, Kanda, Mitsuro, Ishibashi, Keiichiro, Hata, Taishi, Kobayashi, Michiya, Hasegawa, Junichi, Fukunaga, Mutsumi, Takagane, Akinori, Otsuji, Toshio, Miyake, Yasuhiro, Nagase, Michitaka, Sakamoto, Junichi, Matsuoka, Masaki, Oba, Koji, Mishima, Hideyuki
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2015
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4619505/
https://ncbi.nlm.nih.gov/pubmed/26497654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1712-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires